Ongoing clinical trials are exploring whether modulating kinase activity can either suppress the immune response in autoimmune disorders or enhance it for antiviral therapies and cancer immunotherapy.
The discovery and characterization of small molecule modulators have supported these efforts. The Transcreener ADP2 Kinase Assay meets this need by directly detecting ADP to measure the activity of virtually any kinase. This method has been extensively validated for kinase discovery programs since 2007.
This eBook presents five examples of how Transcreener enabled rapid assay development for screening and dose-response measurements.
The innate immunity-associated kinases targeted in the five case studies include:
- AMP-Activated Kinase (AMPK)
- IκB Kinase (IKK-β)
- Interleukin-1 Receptor-Associated Kinase 4 (IRAK4)
- Janus Kinase 1 and 3 (JAK1 and JAK3)
- TANK-Binding Kinase 1 (TBK1)
Download the full eBook now to learn more
About BellBrook Labs
BellBrook Labs is dedicated to providing the pharmaceutical industry with enabling screening tools to accelerate the discovery of more effective therapies. Leveraging its two base platforms, BellBrook has developed assays for hundreds of drug targets.
